论文部分内容阅读
骨髓瘤患者发生实体瘤者已有报导,但发病率及其与抗肿瘤药物的关系尚不清楚。为了确定实体瘤发病中化疗的作用,作者评价了许多骨髓病患者在采用各种左旋溶肉瘤素强的松联合治疗后除白血病以外的癌症的发生率。结果:在628例多发性骨髓瘤患者中,有595例至少生存2个月,可作为对大旋溶肉瘤素生瘤危险进行评价的对象。19例患者(3.2%)在化疗开始后至少2个月才发生实体瘤,19例癌症患者中有16例为男性(84
The occurrence of solid tumors in patients with myeloma has been reported, but the incidence and its relationship with anti-tumor drugs is not clear. To determine the role of chemotherapy in the development of solid tumors, the authors evaluated the incidence of cancers other than leukemia in many patients with myelopathy after treatment with predominant levosarcoma prednisone. RESULTS: Of the 628 patients with multiple myeloma, 595 survived for at least 2 months and could be used as a target for assessing the risk of tumorigenesis of megakaryogenin. Nineteen patients (3.2%) developed solid tumors at least 2 months after the start of chemotherapy, and 16 of 19 patients with cancer were male (84